SIRNA AGAINST CBL-B AND OPTIONALLY IL-2 AND IL-12 FOR USE IN THE TREATMENT OF CANCER

The invention relates to a method for the immune activation of NK cells by the reduction or inhibition of the Cbl-b function in said cells. This stimulates the congenital immune system and thus permits the therapy of appropriate diseases. L'invention concerne un procédé d'activation immuni...

Full description

Saved in:
Bibliographic Details
Main Authors LOIBNER, HANS, HASLINGER, ISABELLA, LAMETSCHWANDTNER, GUNTHER, SEIDL, SANDRA, SCHUSTER, MANFRED
Format Patent
LanguageEnglish
French
Published 10.09.2019
Subjects
BEER
BIOCHEMISTRY
CHEMISTRY
COMPOSITIONS THEREOF
CULTURE MEDIA
ENZYMOLOGY
HUMAN NECESSITIES
HYGIENE
MEDICAL OR VETERINARY SCIENCE
METALLURGY
MICROBIOLOGY
MICROORGANISMS OR ENZYMES
MUTATION OR GENETIC ENGINEERING
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
PROPAGATING, PRESERVING OR MAINTAINING MICROORGANISMS
SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS
SPIRITS
VINEGAR
WINE
Online AccessGet full text

Cover

More Information
Summary:The invention relates to a method for the immune activation of NK cells by the reduction or inhibition of the Cbl-b function in said cells. This stimulates the congenital immune system and thus permits the therapy of appropriate diseases. L'invention concerne un procédé d'activation immunitaire des cellules NK par réduction ou inhibition de la fonction Cb1-b dans ces dernières. Ce procédé a pour effet de stimuler le système immunitaire inné ce qui permet le traitement de pathologies appropriées.
Bibliography:Application Number: CA20112822114